Table 2.

Patient disposition by primary neurological condition^a.

Patient disposition, n	AD/dementia	MS	Stroke/CBVD	TBI	ALS/MND	PD/movement disorders	Other PBA	Total
Enrolled	n = 17	n = 223	n = 51	n = 23	n = 199	n = 23	n = 17	N = 553
Treated ≥6 months	10	176	30	15	126	12	13	382
Treated ≥12 monthsa	5	149	27	10	86	11	12	300
Completed treatment phase	4	149	27	9	85	10	12	296
Remaining at study termination	2	8	4	2	4	0	0	20
Did not complete due to:	11	66	20	12	110	13	5	257
AE	4	27	7	1	62	5	1	107
Medication refusal due to AE	2	10	4	2	18	4	1	41
Medication refusal for other than AE	0	7	1	2	3	0	1	14
Withdrew consent	3	15	3	3	9	1	0	34
Lost to follow-up	0	4	4	2	7	0	1	18
Protocol violation	0	2	0	0	1	0	0	3
Other	4	9	5	4	14	3	1	40
Entered extension phase	4	132	22	8	77	8	11	262

AD: Alzheimer’s disease; AE: adverse event; ALS: amyotrophic lateral sclerosis; CBVD: cerebrovascular disorders; MND: motor neuron disease; MS: multiple sclerosis; PBA: pseudobulbar affect; PD: Parkinson’s disease; TBI: traumatic brain injury.

^aIncludes all patients who completed the treatment phase or received at least 365 days of dosing.